CTLA4 and non-small cell lung carcinoma: In contrast, the overall respiratory, gastrointestinal and endocrine system toxicity was higher with anti-PD-1/PD-L1 in combination with other ICIs for NSCLC than with anti-CTLA-4 plus anti-PD-1/PD-L1 (Table 1).